58 min
HealthTree Podcast for AML: Eytan Stein, MD, Memorial Sloan Kettering HealthTree Podcast for AML
-
- Health & Fitness
The IDH mutation can be found in approximately 20% of adult AML cases. Isocitrate dehydrogenase isoform 1 and 2 or IDH1 and IDH2 mutations are typically found in older AML patients and have an intermediate risk profile, with IDH2 being the more common of the two. There has been the development of targeted therapy drugs, such as IDH inhibitors to address these mutations.
Ivosidenib (Tibsovo) and enasidinib (Idhifa) are IDH inhibitors and were approved for use as monotherapy in relapsed/refractory AML with IDH1 and IDH2 mutations, respectively. Clinical trials have been exploring the use of combinations with other drugs such as azacitidine and venetoclax to improve efficacy and optimize outcomes.
Ivosidenib (Tibsovo) was just recently approved by the FDA in May 2022 for use in combination with azacitidine for newly diagnosed patients age 75 years or older and not fit for intensive chemotherapy.
In this podcast, Dr. Eytan Stein will tell us about IDH mutations, the current treatment options, as well as the recent FDA approval of ivosidenib (Tibsovo) and what that means for the treament landscape.
Thank you to our episode sponsor, Bristol Myers Squibb.
The IDH mutation can be found in approximately 20% of adult AML cases. Isocitrate dehydrogenase isoform 1 and 2 or IDH1 and IDH2 mutations are typically found in older AML patients and have an intermediate risk profile, with IDH2 being the more common of the two. There has been the development of targeted therapy drugs, such as IDH inhibitors to address these mutations.
Ivosidenib (Tibsovo) and enasidinib (Idhifa) are IDH inhibitors and were approved for use as monotherapy in relapsed/refractory AML with IDH1 and IDH2 mutations, respectively. Clinical trials have been exploring the use of combinations with other drugs such as azacitidine and venetoclax to improve efficacy and optimize outcomes.
Ivosidenib (Tibsovo) was just recently approved by the FDA in May 2022 for use in combination with azacitidine for newly diagnosed patients age 75 years or older and not fit for intensive chemotherapy.
In this podcast, Dr. Eytan Stein will tell us about IDH mutations, the current treatment options, as well as the recent FDA approval of ivosidenib (Tibsovo) and what that means for the treament landscape.
Thank you to our episode sponsor, Bristol Myers Squibb.
58 min